Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1215 of 2548 results for methods

  1. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

  2. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

    Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.

  3. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)

    Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

  4. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTG713)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.

  5. Child abuse and neglect (QS179)

    This quality standard covers recognising, assessing and responding to abuse and neglect of children and young people under 18. It covers physical, sexual and emotional abuse. This quality standard describes high-quality care in priority areas for improvement.

  6. Cerebral palsy in adults (QS191)

    This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.

  7. Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.

  8. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  9. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

  10. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

  11. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

  12. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  13. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

    Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.

  14. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

  15. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers